Dublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "High-Throughput Screening Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.
The High-Throughput Screening Market research report provides strategic analysis of technologies, applications, regional adoption, competitive priorities, and emerging opportunities. The market is projected to reach USD 23.24 billion in 2026 and grow at a CAGR of 5.94% to USD 33.44 billion by 2032. Its insights support investment planning, market entry assessment, and the identification of technologies capable of improving discovery productivity.
Market Overview
High-throughput screening (HTS) is a core capability across drug discovery, chemical biology, toxicology, genomics, and precision medicine. Automated liquid handling, robotics, microplate assays, miniaturized workflows, high-content imaging, and advanced analytics allow researchers to evaluate extensive libraries of compounds, biologics, genetic perturbations, and cellular models with greater speed and reproducibility.
Demand is increasingly driven by faster hit identification, reduced reagent consumption, improved assay quality, and stronger translation from early discovery to validation. Laboratories are also adopting organoids, 3D cultures, phenotypic assays, label-free detection, and multiplexed readouts to generate richer biological context.
Transformative Market Shifts
HTS is moving from volume-focused screening toward intelligence-led experimentation. While biochemical assays remain important for target-based research, cell-based and phenotypic approaches are gaining prominence. High-content screening combines microscopy and image analytics to measure morphology, intracellular localization, cytotoxicity, pathway modulation, and multiparametric cellular responses.
Flexible, modular automation is replacing reliance on fixed robotic lines. Configurable platforms can integrate assay development, compound management, incubation, detection, and data capture. Acoustic dispensing and miniaturized plates reduce resource use, while cloud-enabled laboratory systems, electronic lab notebooks, and FAIR data practices improve traceability and collaboration. Understanding these shifts enables organizations to prioritize scalable platforms and reduce technology investment risk.
Artificial Intelligence Impact
Artificial intelligence is improving experimental design, image interpretation, compound prioritization, anomaly detection, and screening decisions. Machine learning can identify subtle phenotypes, reduce false positives, and connect assay results with chemical structures, omics profiles, and biological pathways. Computer vision supports automated segmentation, feature extraction, and phenotype classification.
Active learning models can recommend the next compounds or genetic perturbations to test, improving exploration efficiency. AI also strengthens predictive toxicology, polypharmacology assessment, and structure-activity analysis. Successful adoption requires standardized metadata, transparent validation, quality training data, cybersecurity, and governance addressing bias, reproducibility, and auditability.
Regional and Economic Group Insights
North America remains highly advanced due to pharmaceutical R&D, biotechnology clusters, academic centers, contract research capacity, and regulatory expertise. Europe benefits from coordinated research networks, strong quality standards, advanced cellular models, and emphasis on ethical data governance and alternatives to animal testing.
Asia-Pacific is expanding rapidly through biotechnology investment, genomics capabilities, laboratory modernization, and academic-industry collaboration. China, India, Japan, South Korea, Singapore, and Australia are notable contributors. Latin America is developing capabilities in infectious disease and agricultural biotechnology, while Gulf economies are investing in genomics, precision medicine, and research infrastructure. Africa presents targeted opportunities in infectious diseases, antimicrobial resistance, and neglected tropical diseases.
ASEAN is gaining relevance through government-backed biotechnology initiatives and clinical research connectivity. The EU maintains a mature, collaborative HTS environment, while BRICS markets combine large patient populations with expanding pharmaceutical capacity. G7 countries continue to influence best practices in AI-enabled discovery, biologics, and translational medicine. These comparisons provide a practical foundation for evaluating partnerships and geographic expansion.
Strategic Priorities
. Invest in modular robotics, validated liquid handling, high-content imaging, acoustic dispensing, compound management, and integrated informatics.
. Strengthen assay reliability through appropriate controls, Z-factor assessment, replicate strategies, orthogonal confirmation, and early counter-screening.
. Establish AI-ready data foundations using standardized metadata, controlled vocabularies, harmonized image formats, and interoperable systems.
. Build multidisciplinary teams spanning assay biology, automation engineering, chemoinformatics, data science, quality, and translational research.
. Align HTS investments with therapeutic priorities, validation plans, compliance requirements, and measurable scientific outcomes.
Key Takeaways from This Report
. The market is forecast to reach USD 33.44 billion by 2032 at a 5.94% CAGR.
. Automation, miniaturization, high-content imaging, and phenotypic screening are reshaping discovery workflows.
. AI is enhancing prioritization and interpretation, but data quality and governance remain essential.
. North America and Europe retain mature infrastructures, while Asia-Pacific offers substantial expansion potential.
. Competitive advantage increasingly depends on flexible automation, reproducible assays, interoperable data, and multidisciplinary expertise.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 197 |
| Forecast Period | 2026 - 2032 |
| Estimated Market Value (USD) in 2026 | $23.24 Billion |
| Forecasted Market Value (USD) by 2032 | $33.44 Billion |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
Key Topics Covered:
1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. High-Throughput Screening Market, by Product Type
7.1. Introduction
7.2. Consumables
7.2.1. Labware
7.2.2. Reagents & Assay Kits
7.3. Instruments
7.3.1. Detection Systems
7.3.2. Liquid Handling Systems
7.4. Services
7.4.1. Assay Development & Validation
7.4.2. Screening
7.5. Software
7.5.1. Compound Management
7.5.2. Data Analysis
8. High-Throughput Screening Market, by Technology
8.1. Introduction
8.2. Cell-Based Assays
8.2.1. Fluorometric Imaging Plate Reader Assays
8.2.2. Reporter based Assays
8.3. Lab-on-a-chip Technology (LOC)
8.4. Label-free Technology
8.5. Microfluidics Based
9. High-Throughput Screening Market, by Plate Format
9.1. Introduction
9.2. 1536-well plate
9.3. 384-well plate
9.4. 96-well plate
10. High-Throughput Screening Market, by Application
10.1. Introduction
10.2. Drug Discovery
10.3. Genomics & Proteomics
10.4. Molecular Screening
10.5. Toxicology & Safety Assessment
11. High-Throughput Screening Market, by End User
11.1. Introduction
11.2. Academic & Research Institutes
11.3. Contract Research Organizations
11.4. Hospitals & Diagnostic Labs
11.5. Pharmaceutical & Biotechnology Companies
12. High-Throughput Screening Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. High-Throughput Screening Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. High-Throughput Screening Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Agilent Technologies, Inc.
16.2. Aurora Biomed, Inc.
16.3. Bio-Rad Laboratories, Inc.
16.4. Biomat S.r.l
16.5. BMG LABTECH GmbH
16.6. BRAND GMBH + CO KG
16.7. Charles River Laboratories International, Inc.
16.8. Corning Incorporated
16.9. Creative Biolabs, Inc.
16.10. Danaher Corporation
16.11. DIANA Biotechnologies, a.s
16.12. Eppendorf SE
16.13. EUROFINS SCIENTIFIC SE
16.14. Gilson Company, Inc.
16.15. Hamilton Company
16.16. HighRes BioSolutions, Inc.
16.17. Lonza Group AG
16.18. Merck KGaA
16.19. Mettler Toledo International, Inc.
16.20. PerkinElmer, Inc.
16.21. Revvity, Inc.
16.22. Sartorius AG
16.23. Tecan Trading AG
16.24. Thermo Fisher Scientific Inc.
16.25. Waters Corporation
17. Key Experts
For more information about this report visit https://www.researchandmarkets.com/r/ofnv1d
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
